4 Gene Therapy Companies to Watch

What gene therapy companies should be on investors' radar? Here are four promising companies to consider looking at in 2018.

AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data

AveXis (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will...

Genetics Update: Q1 in Review

With Q1 2018 officially in the books, here the Investing News Network takes a look back at what some of...

AveXis’ Share Price Soars with Acquisition Announcement

Global big pharma company Novartis started the week off on the right foot by announcing plans to acquire gene therapy...

AveXis Enters Agreement to be Acquired by Novartis AG for $8.7 billion

AveXis (NASDAQ:AVXS) announced today that it has entered into an agreement and plan of merger with Novartis pursuant to which...

AveXis Enters into Licensing Agreement with Genethon

AveXis (NASDAQ:AVXS) and Genethon today announced they have entered into an exclusive, worldwide license agreement for in vivo gene therapy delivery of...

4 Gene Editing Technologies Explained

We look at four types of gene editing currently in clinical trials, as well as the pros and cons of...